Citadel Advisors
RCUS icon

Citadel Advisors’s Arcus Biosciences RCUS Stock Holding History

Citadel Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.74M Sell
80,500
-14,100
-15% -$305K ﹤0.01% 6391
2025
Q4 		$2.25M Sell
94,600
-8,900
-9% -$182K ﹤0.01% 5682
2025
Q3 		$1.41M Buy
103,500
+27,500
+36% +$286K ﹤0.01% 6792
2025
Q2 		$619K Buy
76,000
+42,800
+129% +$366K ﹤0.01% 8132
2025
Q1 		$261K Sell
33,200
-6,100
-16% -$70.7K ﹤0.01% 9896
2024
Q4 		$585K Buy
39,300
+23,600
+150% +$385K ﹤0.01% 8214
2024
Q3 		$240K Buy
15,700
+12,900
+461% +$203K ﹤0.01% 9773
2024
Q2 		$42.6K Sell
2,800
-17,400
-86% -$281K ﹤0.01% 11940
2024
Q1 		$381K Buy
20,200
+1,700
+9% +$29.4K ﹤0.01% 8954
2023
Q4 		$353K Sell
18,500
-400
-2% -$6.39K ﹤0.01% 8820
2023
Q3 		$339K Sell
18,900
-15,900
-46% -$319K ﹤0.01% 8915
2023
Q2 		$707K Buy
34,800
+12,000
+53% +$228K ﹤0.01% 7180
2023
Q1 		$416K Buy
22,800
+6,400
+39% +$122K ﹤0.01% 8684
2022
Q4 		$339K Buy
+16,400
New +$451K ﹤0.01% 9050
2022
Q3 		– Sell
-58,500
Closed -$1.48M – 13436
2022
Q2 		$1.48M Buy
58,500
+50,300
+613% +$1.23M ﹤0.01% 6151
2022
Q1 		$259K Sell
8,200
-4,100
-33% -$137K ﹤0.01% 10924
2021
Q4 		$498K Buy
+12,300
New +$477K ﹤0.01% 9706
2021
Q3 		– Sell
-32,800
Closed -$901K – 14501
2021
Q2 		$901K Buy
32,800
+22,300
+212% +$637K ﹤0.01% 8629
2021
Q1 		$295K Buy
+10,500
New +$365K ﹤0.01% 10899
2020
Q4 		– Sell
-85,000
Closed -$1.46M – 11419
2020
Q3 		$1.46M Buy
+85,000
New +$1.9M ﹤0.01% 5327

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citadel Advisors's RCUS Position: Q1 2026 in Review

Citadel Advisors increased its Arcus Biosciences (RCUS) stake by 1,170% in Q1 2026, buying an estimated $26.5M and bringing the position to 1,329,935 shares worth $28.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1909.

Citadel Advisors first reported a position in RCUS in Q1 2019 and has held it in 29 quarters since. The position peaked at $32.2M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Citadel Advisors held 1,329,935 shares of Arcus Biosciences worth $28.7M as of Q1 2026.
  • Citadel Advisors bought 1,225,234 Arcus Biosciences shares in Q1 2026, an estimated $26.5M.
  • Arcus Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #1909 holding.
  • Citadel Advisors first reported a position in Arcus Biosciences in Q1 2019 and has held it in 29 quarters since.
  • Citadel Advisors's Arcus Biosciences position peaked at $32.2M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.